Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients.
Ontology highlight
ABSTRACT: The COVID-19 pandemic has prompted an international effort to develop and repurpose medications and procedures to effectively combat the disease. Several groups have focused on the potential treatment utility of angiotensin-converting-enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) for hypertensive COVID-19 patients, with inconclusive evidence thus far. We couple electronic medical record (EMR) and registry data of 3,643 patients from Spain, Italy, Germany, Ecuador, and the US with a machine learning framework to personalize the prescription of ACEIs and ARBs to hypertensive COVID-19 patients. Our approach leverages clinical and demographic information to identify hospitalized individuals whose probability of mortality or morbidity can decrease by prescribing this class
SUBMITTER: Bertsimas D
PROVIDER: S-EPMC7958102 | biostudies-literature | 2021 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA